

**Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting**

600 East Broad Street – 1st Floor Conference Rooms
Richmond, Virginia 23219

Thursday, June 27, 2023 - 1:00 p.m.

Welcome and Comments from DMAS' Director

Cheryl Roberts, JD Medicaid Director

Call to Order

Lisa Price Stevens MD, CMO, Chair

Drug Utilization Review (DUR) Board Update

Rachel Cain, PharmD

Approval of Minutes from March 21, 2024 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

Old business

PDL Quarter 2 – New Drug Review (Therapeutic Class)

Potential New Drug Class

- Colony Stimulating Factors (Potential New Closed Class)
- Hepatitis B (Potential New Closed Class)
- Duchenne Muscular Dystrophy (Potential New Closed Class)

New Biosimilars

- Tyenne (tocilizumab-aazg) (Cytokine and CAM Antagonists) (Closed Class)
- Simlandi (adalimumab-ryvk) (Cytokine and CAM Antagonists) (Closed Class)

Generics Drugs and New Dosage Forms

- Clobetasol propionate 0.05% (Ophthalmics, Anti-Inflammatory)
- Bromfenac sodium 0.075% (Ophthalmics, Anti-Inflammatory)
- Fluorometholone 0.1% (Ophthalmics, Anti-Inflammatory)
- Hemlibra (emicizumab-kxwh) (Hemophilia Treatment)

PDL Quarter 2– Annual Review -

Antivirals

- Hepatitis C Agents (Closed Class)
- HIV (Closed Class)

Cardiac Medications

- Angiotensin Modulator Combinations
- Angiotensin Modulators II (includes Direct Renin Inhibitors & combination products)
- Antihypertensives, Sympatholytics^
- Beta Blockers (includes combination products)^
- Calcium Channel Blockers (includes dihydropyridine and non-dihydropyridine agents)^
- Lipotropics, Other (includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibric Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents)
- Lipotropics, Statins

- Pulmonary Arterial Hypertension Agents, Oral/Inhaled/Injectable (includes Endothelin-1 agents, PDE-5 Inhibitors, Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators)

Endocrine & Metabolic Agents Oral

- Glucocorticoids, Oral
- Growth Hormones (Closed Class)
- Glucagon Agents (Closed Class)
- HAE Treatments
- Progestins for Cachexia^
- Weight Management Agents (Closed Class)

Gastrointestinal

- Antiemetic/Antivertigo Agents
- GI Motility, Chronic
- H. pylori Agents
- Histamine II Receptor Antagonists^
- Proton Pump Inhibitors
- Ulcerative Colitis

Respiratory

- Anti-Allergens, Oral
- Antibiotics, Inhaled (Closed Class)
- Antihistamines, Minimally Sedating
- Bronchodilators, Beta Agonist
 - a. Bronchodilators, Long-Acting Beta Adrenergics
 - b. Bronchodilators, Short Acting Beta Adrenergics
- COPD Agents (Closed Class)
- Cough & Cold Agents (Legend)^
- Epinephrine, Self-Injected
- Glucocorticoids (includes nebulized solutions, metered dose inhalers and combinations) (Closed Class)
- Intranasal Rhinitis (includes Antihistamines and Corticosteroids)
- Leukotriene Modifiers

^Discussions for removal from the PDL

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Phase II New Drugs*

P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes*

P&T Committee Members

Bylaw Review and Update

P&T Committee Members

Announcements

P&T Committee Members

Next Meeting - October 9, 2024.

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will allocate time slots for interested parties to present scientific and clinical information on PDL Phase I drugs in classes in which are scheduled for review at the September meeting and new PDL Phase II drugs listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – June 2023 to present
- **New** Drugs in PDL Phase I or II Drug Classes – June 2022 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The Chairperson will approve presentation requests based on relevancy of the information.

Anyone interested in providing specific clinical information to the Committee at the meeting must **submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter.** Please send requested information to pdlinput@dmas.virginia.gov and david.damico@primetherapeutics.com by 5 p.m. EST on Thursday, May 30, 2024.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by 5 p.m. EST on Thursday, May 30, 2024.